In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...
Drug maker Moderna 's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook ...
The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...
The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded ...
Moderna provided updates on key elements of its pipeline, including a next-generation COVID-19 vaccine, an RSV vaccine, a new ...
"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.